BeyondSpring Pharmaceuticals Provides Quarterly Operational Update And Full Year 2016 Results

NEW YORK, April 28, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ Capital Markets:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, today provided an operational update to the investment community, including financial results for the year ended December 31, 2016.

"In our first earnings report as a public company, we are pleased to provide the investment community with an update on our operations and insight into our clinical pipeline,” said Dr. Lan Huang, Ph.D., BeyondSpring CEO. β€œIn March 2017, BeyondSpring successfully completed its initial public offering and concurrent private placement with Chinese and U.S. investors, significantly strengthening our balance sheet with an additional $48.17 million in total net proceeds.”

Back to news